<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39328554</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Timing is essential: Humoral and cellular responses to SARS-CoV-2 vaccination in a cohort of patients with auto-immune diseases treated with rituximab.</ArticleTitle><Pagination><StartPage>e38043</StartPage><MedlinePgn>e38043</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e38043</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e38043</ELocationID><Abstract><AbstractText>Rituximab (RTX), an anti CD20 monoclonal antibody, is now a gold standard treatment for several auto-immune and chronic inflammatory diseases. Receiving RTX exposes patients to more severe infections as vaccinations become virtually inefficient in terms of B cell responses. During the COVID-19 crisis, RTX-exposed patients exhibited more severe forms of the disease, and in some cases, the introduction of RTX was delayed or avoided to protect patients as much as possible against SARS-CoV-2 infections. We retrospectively collected cellular and humoral responses from thirteen patients with dermatological and rheumatological autoimmune diseases who had been vaccinated after receiving RTX. Memory T cells subsets from patients that exposed to RTX showed few differences when compared to a cohort of healthy donors. The IFN<b>ᵧ</b> ELISpot assay using SARS-CoV-Prot_S1 showed that eight patients exhibited a positive response that was neither correlated to the time between RTX infusion and the sampling nor to the time between RTX and the vaccination. Conversely, analysis of the SARS-CoV-2 serology showed a clearly lower binding antibody units per mL in case of recent RTX infusion. The safe threshold forconsistently positive serology was to vaccinate at least 300 days after RTX infusion (p = 0.02). Our data illustrate the difficulty in obtaining a satisfactory response to vaccination after RTX treatment within almost a year after the latest infusion, and emphasize the need to better evaluate the risk of relapses in auto-immune diseases before administering RTX in order to maintain RTX only in patients whose medical situation requires it.</AbstractText><CopyrightInformation>© 2024 The Authors. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gallais Sérézal</LastName><ForeName>Irène</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Besançon University Hospital, Besançon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Franche-Comté, EFS, INSERM UMR RIGHT, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spehner</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Université de Franche-Comté, EFS, INSERM UMR RIGHT, Besançon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm CIC-1431, CHU Besançon, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kroemer</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Université de Franche-Comté, EFS, INSERM UMR RIGHT, Besançon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Besançon University Hospital, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourezane</LastName><ForeName>Inès</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Université de Franche-Comté, EFS, INSERM UMR RIGHT, Besançon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Besançon University Hospital, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meaux-Ruault</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Besançon University Hospital, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prati</LastName><ForeName>Clément</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Besançon University Hospital, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastissier</LastName><ForeName>Andréa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Besançon University Hospital, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lodovichetti</LastName><ForeName>Juliette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Besançon University Hospital, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiberghien</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Université de Franche-Comté, EFS, INSERM UMR RIGHT, Besançon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Etablissement Francais Du Sang, La Plaine-Saint Denis, Saint-Denis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aubin</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Besançon University Hospital, Besançon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Franche-Comté, EFS, INSERM UMR RIGHT, Besançon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors have no conflict of interest to declare, please see statement in the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39328554</ArticleId><ArticleId IdType="pmc">PMC11425176</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e38043</ArticleId><ArticleId IdType="pii">S2405-8440(24)14074-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Joly P., Maho-Vaillant M., Prost-Squarcioni C., Hebert V., Houivet E., Calbo S., Caillot F., Golinski M.L., Labeille B., Picard-Dahan C., Paul C., Richard M.-A., Bouaziz J.D., Duvert-Lehembre S., Bernard P., Caux F., Alexandre M., Ingen-Housz-Oro S., Vabres P., Delaporte E., Quereux G., Dupuy A., Debarbieux S., Avenel-Audran M., D'Incan M., Bedane C., Bénéton N., Jullien D., Dupin N., Misery L., Machet L., Beylot-Barry M., Dereure O., Sassolas B., Vermeulin T., Benichou J., Musette P. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;6736:1–10. doi: 10.1016/S0140-6736(17)30070-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30070-3</ArticleId><ArticleId IdType="pubmed">28342637</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N., Madhira V., Hu C., Olex A.L., Bergquist T., Fitzgerald K.C., Huling J.D., Patel R.C., Singh J.A. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: a retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C) Semin. Arthritis Rheum. 2023;58 doi: 10.1016/j.semarthrit.2022.152149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152149</ArticleId><ArticleId IdType="pmc">PMC9729169</ArticleId><ArticleId IdType="pubmed">36516563</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroon F.P.B., Najm A., Alunno A., Schoones J.W., Landewé R.B.M., Machado P.M., Navarro-Compán V. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann. Rheum. Dis. 2022;81:422–432. doi: 10.1136/annrheumdis-2021-221575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221575</ArticleId><ArticleId IdType="pubmed">34876462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zonozi R., Walters L.C., Shulkin A., Naranbhai V., Nithagon P., Sauvage G., Kaeske C., Cosgrove K., Nathan A., Tano-Menka R., Gayton A.C., Getz M.A., Senjobe F., Worrall D., Iafrate A.J., Fromson C., Montesi S.B., Rao D.A., Sparks J.A., Wallace Z.S., Farmer J.R., Walker B.D., Charles R.C., Laliberte K., Niles J.L., Gaiha G.D. T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19. Sci. Transl. Med. 2023;15 doi: 10.1126/scitranslmed.adh4529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adh4529</ArticleId><ArticleId IdType="pubmed">38019932</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolf A., Wiberg A., Müller M., Nazir F.H., Pavlovic I., Laurén I., Mangsbo S., Burman J. Factors associated with serological response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with rituximab. JAMA Netw. Open. 2022;5 doi: 10.1001/jamanetworkopen.2022.11497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.11497</ArticleId><ArticleId IdType="pmc">PMC9096596</ArticleId><ArticleId IdType="pubmed">35544139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmich B., Sanchez-Alamo B., Schirmer J.H., Berti A., Blockmans D., Cid M.C., Holle J.U., Hollinger N., Karadag O., Kronbichler A., Little M.A., Luqmani R.A., Mahr A., Merkel P.A., Mohammad A.J., Monti S., Mukhtyar C.B., Musial J., Price-Kuehne F., Segelmark M., Teng Y.K.O., Terrier B., Tomasson G., Vaglio A., Vassilopoulos D., Verhoeven P., Jayne D. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann. Rheum. Dis. 2023;2015:30–47. doi: 10.1136/ard-2022-223764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223764</ArticleId><ArticleId IdType="pubmed">36927642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignard C., Maho-Vaillant M., Golinski M.L., Balayé P., Prost-Squarcioni C., Houivet E., Calbo S., Labeille B., Picard-Dahan C., Konstantinou M.P., Chaby G., Richard M.A., Bouaziz J.D., Duvert-Lehembre S., Delaporte E., Bernard P., Caux F., Alexandre M., Ingen-Housz-Oro S., Vabres P., Quereux G., Dupuy A., Debarbieux S., Avenel-Audran M., D'Incan M., Bédane C., Bénéton N., Jullien D., Dupin N., Misery L., Machet L., Beylot-Barry M., Dereure O., Sassolas B., Benichou J., Joly P., Hébert V. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. JAMA Dermatology. 2020;156:545–552. doi: 10.1001/jamadermatol.2020.0290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2020.0290</ArticleId><ArticleId IdType="pmc">PMC7081151</ArticleId><ArticleId IdType="pubmed">32186656</ArticleId></ArticleIdList></Reference><Reference><Citation>Troldborg A., Thomsen M.K., Bartels L.E., Andersen J.B., Vils S.R., Mistegaard C.E., Johannsen A.D., Hermansen M.L.F., Mikkelsen S., Erikstrup C., Hauge E.M., Ammitzbøll C. Time since rituximab treatment is essential for developing a humoral response to COVID-19 mRNA vaccines in patients with rheumatic diseases. J. Rheumatol. 2022;49:644–649. doi: 10.3899/jrheum.211152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.211152</ArticleId><ArticleId IdType="pubmed">35232803</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijenthira A., Gong I., Betschel S.D., Cheung M., Hicks L.K. Vaccine response following anti-CD20 therapy: a systematic review and meta-Analysis of 905 patients. Blood Adv. 2021;5:2624–2643. doi: 10.1182/bloodadvances.2021004629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021004629</ArticleId><ArticleId IdType="pmc">PMC8216656</ArticleId><ArticleId IdType="pubmed">34152403</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>